Introduction
Styrene is suspected to cause lympho-hematopoietic malignancies (1, 2) . However, we are still unable to calculate the cancer risk for workers exposed to styrene using human epidemiological data (3) . The rad-equivalence method has been suggested as a basis for cancer risk estimation when no appropriate human cancer data are available to calculate cancer risk associated with occupational exposure (4) (5) (6) (7) (8) . Cancer risks of some genotoxic chemicals have been calculated by the radequivalence method and have been shown to give results in accordance with cancer test data (6) .
The rad-equivalence method starts from an exact determination of the target dose associated with an occupational exposure to the carcinogen (6) . The target dose of the carcinogen in the immediate surrounding of DNA needs then to be expressed as an equivalent radiation dose. This conversion step requires an accurate determination of the relative genotoxic potency (Q) i.e. the dose of c radiation that produces the same genotoxic response as a certain dose of the chemical (8) (9) (10) ). The cancer risk can then be calculated since the cancer risk per unit c radiation has been well described (11, 12) . The lifetime risk for fatal lymphohematopoietic cancer (R c ) associated with ionizing radiation has been estimated to be $0.04 excess deaths per 10 3 persons exposed to 0.01 gray (51 rad) (11) . Multiplying R c with Q of the carcinogen under study and with the dose of the carcinogen yields the estimated cancer risk (P).
One of the major assumptions of the rad-equivalence model is that risks are estimated at doses or dose rates so low that the promoting and modifying influences of the agent under consideration are negligible. Under these conditions, it seems permissible to assume that other promoting and modifying factors affect an initiated cell to the same extent, irrespective of whether initiation was induced by the chemical or c radiation (8) . In order to apply the approach to styrene, we need to determine the target and/or blood dose associated with an exposure to styrene and a value of Q for styrene 7,8-oxide.
Styrene (IARC, 2B: possibly carcinogenic to humans) is metabolized to the electrophile styrene 7,8-oxide, which is considered to be the ultimate mutagen (International Agency for Research on Cancer, 2A: probably carcinogenic to humans) capable of binding to DNA and hemoglobin (Hb) (3) . Laboratory and human studies have shown that styrene exposure can cause DNA adducts of styrene 7,8-oxide, e.g. N-7-adducts on guanine (13) (14) (15) . Styrene 7,8-oxide DNA adducts can induce gene mutations including point mutations and chromosome mutations (14, (16) (17) (18) (19) .
The dose is defined as the integral over time of the dose rate of the initiating agent (20, 21) . For chemicals, the dose rate (mMh/h) is equal to the concentration (in mM) of the mutagenic compound or the metabolite in target tissues. The dose of styrene 7,8-oxide in blood is considered as a surrogate for the target dose, i.e. the dose of the ultimate mutagen in the immediate vicinity of DNA (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . The styrene 7,8-oxide concentration can either be measured in blood directly or derived from adducts to Hb (4, (22) (23) (24) (25) . An alternative method is to estimate blood styrene 7,8-oxide concentration by means of physiologically based toxicokinetic models (26) (27) (28) radiation by studying forward mutation to streptomycin nondependence in a streptomycin-dependent Escherichia coli SD4 strain. The aims of the current investigation were to determine the blood dose associated with an occupational exposure to styrene and an accurate determination of Q for styrene 7,8-oxide in order to calculate the lifetime risk for fatal lympho-hematopoietic cancer of workers exposed to styrene by means of the radequivalence approach.
Materials and methods
Comparison of genotoxic potency of styrene 7,8-oxide and c radiation For the estimation of the Q factor of styrene 7,8-oxide, we took into account available mutagenicity data. Nishi et al. (30) compared 6-thioguanine-resistant mutation in Chinese hamster V79 cells induced by 0.08-0.8 mM styrene 7,8-oxide (3-h exposure) and 0.5-10 gray (550-1000 rad) c radiation. Jenssen and Ramel (31) and Beije and Jenssen (32) studied 6-thioguanine-resistant mutations in Chinese hamster V79 cells. Cells were exposed to respectively X-rays (0-400 rad) (31) and to 0 (4 h), 0.52 and 1.04 mM styrene 7,8-oxide during 2 h (D. Jenssen, personal communication). Hussain et al. (unpublished data) compared forward mutations to streptomycin in E. coli SD4 cells exposed to styrene 7,8-oxide (0.6-10 mM) and c radiation (25-100 gray 5 2500-10000 rad) during 1 h.
Additionally, we carried out a comparative in vitro genotoxicity study (single-cell gel electrophoresis and micronuclei assays) with styrene 7,8-oxide and c radiation (33) . In this paper, we only refer to the data of micronucleus frequencies in binucleated cells, since the single-cell gel electrophoresis assay is rather considered to measure repairable DNA damage and not fixed mutations (34) . In contrast, micronuclei arise from whole lagging chromosomes or acentric chromosome fragments detaching from a chromosome after breakage (clastogenic event) (35) . Consequently, the micronucleus assay provides a measure of both chromosome breakage and chromosome loss.
In brief, after informed consent, 20 non-smoking students [15 females, five males, mean (AESD) age 22.0 (AE2.0)] volunteered to participate. Each participant filled in a questionnaire on alcohol and consumer habits, medical and family history, hobbies, etc. The study protocol was approved by the Bioethics committee of the Katholieke Universiteit Leuven. Blood samples were taken by venipuncture in heparinized Vacutainers. Mononuclear leukocytes were isolated by means of a Ficoll-Paque density gradient (34, 36) . Cultures of isolated leukocytes (15% fetal calf serum, 2% phytohemagglutinin in Ham's F10) were immediately prepared and incubated at 37°C. After 24 h, the isolated leukocytes were suspended in the medium containing final concentrations of 0.1, 0.2 or 0.3 mM styrene 7,8-oxide (Chemical Abstracts Service number: 96-09-3; purity . 97%; Sigma-Aldrich, St Louis, MO, USA) or 1% dimethylsulfoxide. Ficoll-Paque-isolated peripheral blood mononuclear cells in 1% dimethylsulfoxide were used as negative control or exposed to different doses of c radiation (1, 2, 3 gray 5 100, 200, 300 rad, respectively) produced by a 60 Co source. The doses of styrene 7,8-oxide and c radiation were selected based on published genotoxicity studies (9, 10, 37, 38) . The cultures were maintained at 37°C for 60 min. After removal of the medium, the medium was renewed and cells were incubated for a further 48 h for the micronucleus test. The micronuclei in binucleated cells were scored per culture (1000 in total). Data are presented as frequencies of micronucleated binucleates per 1000 binucleates. All coded slides were analyzed with an Olympus light microscope (Â1250 magnification) by a single blinded scorer.
Determination of blood dose
The blood dose per hour ( _ D h ) corresponding to the target concentration was estimated using data of exposure studies in volunteers and field studies in workers measuring styrene 7,8-oxide (22, 24, 39, 40) . In addition, we used the toxicokinetic model developed by Csanády et al. (27) as well. The model was programmed in Visual Basic for Microsoft Office Excel 2003. We validated the model by comparing the kinetic data in styrene and styrene 7,8-oxide exposed mice, rats and humans with modeled data as presented in Csanády et al. (27) . We also used the data of Tornero-Velez and Rappaport (28) who modified the model of Csanády (26) to assess the relative contributions of styrene 7,8-oxide derived from direct inhalation and from styrene metabolism to the systemic dose in humans.
Styrene 7,8-oxide blood concentrations (see appendix) were also derived from N-terminal valine adduct levels measured in biomonitoring studies (40, 41) . The following formula was used: _ D h 5 1/k Â (N-terminal valine adduct) Â 2/t er , with the rate constant for formation of adducts of styrene oxide with N-terminal valine of Hb: k 5 9.5 Â 10
À6 liter blood /h/g Hb and the total exposure period of erythrocytes: t er 5 720 h (erythrocyte life span 5 18 weeks and exposure time/ week 5 40 h) (4,27).
Cancer risk estimation
We applied the rad-equivalence approach in order to calculate the lifetime risk for fatal lympho-hematopoietic cancer of styrene-exposed workers (8 h/day, 5 days/week) (4) . From _ D h , an annual dose received during working hours ( _ D ann ) was calculated taking into account 45 workweeks per year and 40 working hours per workweek (see Appendix). Cancer risk per ppm per year (P) was then calculated by multiplying _ D ann with the estimate of the lympho-hematopoietic cancer mortality risk for c radiation (5 0.04 Â 10
À3
/rad) and the genotoxicity potency factor Q obtained from the in vitro study and literature (11) . A detailed outline of the procedure, a description of the applied formula's and values can be found in the appendix.
Statistics
Repeated measures analysis of variance (ANOVA) was carried out to assess the genotoxicity at different doses. Per agent, a linear regression model was built with the MNCB as dependent parameter and dose as independent parameter. Linear regression analyses were carried out with Statistica package, version 6.1 (Statsoft, Tulsa OK, USA). The level of significance was set at P , 0.05 for all statistical analyses.
Results
Comparison of genotoxic potency of styrene 7,8-oxide and c radiation In this study, we evaluated the micronucleus frequencies in lymphocytes induced by styrene 7,8-oxide and c radiation. Per agent, three doses have been tested, together with a common control. Results are represented in Table I . Repeated Measures ANOVA revealed a significant influence of dose on MNCB in the cells treated with styrene 7,8-oxide and c radiation (both P , 0.001). Q is defined as the response increment per dose unit c radiation and can be deduced from the slopes of the regression line between MNCB and the respective dose per agent (8) . This estimation for Q of styrene 7,8-oxide is in line with the mutagenicity data of Nishi et al. (30) . They found an increase in the number of 6-thioguanine-resistant mutants per 10 6 viable cells over the control values of 0.22 per lg/ml and 24 per gray for styrene 7,8-oxide and c radiation, respectively. These values correspond to a genotoxic potency factor Q of 37 rad/mMh (0.0092 gray/mg/liter 5 110.14 rad/mmol/liter 5 37 rad/mMh). In contrast, a lower Q factor of 22 rad/mMh was found by comparing the regression slopes of the dose-response curves for the induction of 6-thioguanine-resistant mutations by X-rays (0.022/rad) and styrene 7,8-oxide (0.48/mMh) in the studies of Jenssen and Ramel (31) 
Determination of blood dose
Blood concentration of styrene 7,8-oxide after 1 ppm styrene exposure in occupational settings has been determined using results of exposure studies in volunteers, data from biomonitoring studies in workers or the toxicokinetic model (Table II) . 
À6 mM corresponding to 1 ppm styrene exposure (Table  II) 
Field studies in workers exposed to styrene. Korn et al. (22) carried out a field study in 13 workers exposed to styrene concentrations between 10 and 73 ppm. Hb adduct levels represent a measure of biologically effective dose and are considered to provide good estimates of target dose (4) . Based on the slope of the regression equation, we can estimate that exposure to 1 ppm styrene would lead to an increased Hb adduct level of 0.21 pmol/g Hb. In a previous study, we determined N-terminal valine adducts in 44 workers (44 referents) exposed to styrene at exposure levels ranging between 0-37 ppm (mean 10 ppm) (41) . We found lower increases of Hb adducts (0.10 pmol/g Hb per ppm styrene). From this, an estimate of blood styrene 7,8-oxide equal to 0.03 Â 10 À6 mM was obtained as explained in the methods and as illustrated in the Appendix. The formation rate constant of phenylhydroxyethyl adduct to Hb was set at 9.5 Â 10
À6
liter blood /h/g Hb (27) . In both studies, styrene air concentrations 
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were inferred from data on glycol concentrations in blood (40) and mandelic acid concentrations in urine (40, 41) .
Toxicokinetic modeling. The model of Csanády et al. (27) was used to predict _ D h after occupational exposure to 1 ppm styrene. Modeling was done using the human physiological, physicochemical and biochemical parameters and absorption rate constants as described in Csanády et al. (27) . Occupational exposure was programmed as follows: styrene exposure during 8 h/day, 5 days/week. The formation rate constant in humans of styrene 7,8-oxide adducts to Hb was set at 9.5 Â 10
À6 liter blood / h/g Hb (27) . The simulation (Figure 3 ) was done setting the alveolar ventilation 5 300 liter air /h and the cardiac output 5 372 liter blood /h (27, 28) . The venous blood styrene 7,8-oxide concentration during occupational exposure to 1 ppm was on average 0.23 Â 10 À6 mM. Tornero-Velez and Rappaport (28) also carried out simulations with a modified model of Csanády et al. (26) to assess relative contributions of styrene 7,8-oxide derived from direct inhalation and from styrene metabolism to the blood dose in humans. They postulated that styrene 7,8-oxide enters the blood from hepatic metabolism of styrene at a lower rate than from direct absorption following inhalation. As a consequence, they calculated a much lower styrene 7,8-oxide blood concentration after exposure to 1 ppm styrene of 0.01 lg/ liter blood (equivalent to 0.08 Â 10 À6 mM) (28) compared to the results of the Csanády model (27) .
Cancer risk estimate associated with occupational exposure to 1 ppm styrene The lympho-hematopoietic cancer mortality risk for c radiation has been estimated at 0.04 Â 10 À3 /rad (11). In Table III , an overview of the cancer risk estimations is given per blood dose received during working hours and Q for styrene 7,8-oxide derived in the present study. We did not take into account blood 
Discussion
Cancer risk estimations based on the rad-equivalence method start with the determination of the blood dose in humans exposed to the carcinogen under study (4) (5) (6) (7) (8) . Our estimations, based on different sources, gave an average styrene 7,8-oxide blood concentration, during exposure to 1 ppm styrene ranging between 0.03 Â 10 À6 and 1.2 Â 10 À6 mM. The upper limit of the range was obtained from studies measuring styrene 7,8-oxide in blood using an indirect analytical method (39, 40) . Both studies revealed a three times higher blood concentration than observed in studies determining styrene 7,8-oxide directly and were considered to overestimate the styrene 7,8-oxide concentration (24) . The lower styrene 7,8-oxide concentrations were derived from studies of Tornero-Velez (28, 42) and Nterminal valine adduct levels in workers exposed to styrene (40, 41) . The resulting styrene 7,8-oxide concentrations were a factor 2-10 lower than the styrene 7,8-oxide blood concentration of other studies measuring styrene 7,8-oxide directly in venous blood (22, 24) . Tornero-Velez (28, 42) postulated that styrene 7,8-oxide enters the blood from hepatic metabolism of styrene at a lower rate than from direct absorption following inhalation. Since styrene 7,8-oxide co-exposure could have varied among workers and within workers over time, styrene 7,8-oxide blood concentrations after exposure to 1 ppm styrene (Table II) could be biased high in some studies, due to unmeasured co-exposures to styrene 7,8-oxide. This could also be important for cancer risk, since direct exposure to styrene 7,8-oxide is likely to be 500-1000 times more potent than styrene at producing styrene 7,8-oxide in blood. However, this could not be assessed since most of the published studies did not carry out styrene 7,8-oxide and styrene measurements in the air.
A second element in the rad-equivalence method is the determination of the dose of a carcinogen that produces the same level of genotoxic response per c radiation dose. The Q factors obtained from micronucleus and mutagenicity data ranged between 22 and 208 rad/mMh. Bacterial cells seemed more sensitive to styrene 7,8-oxide-induced DNA damage than mammalian cells, as a consequence, the actual Q value lays probably close to the median value of 37 rad/mMh. More studies will be necessary to confirm this. Although available for styrene 7,8-oxide and c radiation, we did not consider in vitro-induced genotoxicity assessed with single-cell electrophoresis and sister chromatid exchange assays because of mechanistic considerations (30, 33) . Both parameters are rather markers of exposure than of effect. Interestingly, both studies indicated that styrene 7,8-oxide in the applied dose ranges is able to induce a relative high amount of DNA strand breaks and a high incidence of sister chromatid exchanges but relatively few 6-thioguanine-resistant mutations. In contrast, c radiation tends to induce 6-thioguanineresistant mutations much more than sister chromatid exchanges and DNA strand breaks.
According to our calculations, an exposure to 1 ppm styrene for 1 year would lead to a median estimate of 0.21 extra lymphohematopoietic cancers in 10 6 exposed individuals (range 0.05 Â 10 À6 and 6.22 Â 10
À6
). Taking into account a professional career of 40 years and an exposure to 20 ppm styrene gives a lifetime cancer risk median estimate of 170 lympho-hematopoietic cancers in 10 6 workers (range 37 Â 10 À6 and 4970 Â 10
). Greim (43) estimated cancer risk associated with a 40 years exposure during work time to styrene (20 ppm) to range between 17 and 75 per 10 6 exposed persons. This value is $2 to 10 times lower than our median lifetime cancer risk estimate. We consider our worstcase cancer risk of 4970 lympho-hematopoietic cancers in 10 6 workers as an overestimation (see also Discussion concerning Q value derived from bacterial cells), since it is not supported by epidemiological research, finding little or no increase of lymphohematopoietic cancers in workers exposed to styrene (1, 44) .
Cancer risk assessments always need to deal with assumptions and uncertainties, which induce variations in the final results. The estimates of Greim (43) were based on experimental long-term studies with animals, and consequently need to deal with interspecies differences and extrapolations from high to low dose, of which the uncertainty is basically impossible to determine (45) . The rad-equivalence approach suffers mainly from two sources of variation: the estimates of styrene 7,8-oxide dose and Q values are each responsible for an uncertainty factor of about one order of magnitude. Although there are indications that Q values obtained in mammalian cells and in intact mammals are approximately the same, e.g. for ethylene oxide, one still needs to be careful while extrapolating from the in vitro results (single exposure) to the in vivo situation (repeated and more continuous exposure) since mutagenic response of cells will be different in culture than in tissue (8) . Furthermore, the lympho-hematopoietic cancer risk estimates associated with ionizing radiation are mainly based on population studies following an acute exposure (Japanese Abomb survivors) and consequently are subject to uncertainty for risk assessments associated with chronic exposure (11) .
A prerequisite for cancer risk estimations using rad equivalence is that the applied tests are well-established test systems that are predictive for cancer risk. However, so far, it is not clear whether or which of the applied assays most accurately reflect the genotoxic potency of this class of carcinogens to humans. Mutagenicity testing and the micronucleus assay seem to be promising; however, caution is necessary and more research on the predictivity of genotoxicity assays is necessary (46) (47) (48) (49) .
This paper uses a principle approach to estimate cancer risks, in this case from styrene, using in vivo doses of styrene 7,8-oxide from styrene exposure and in vitro mutagenicity data. The median estimated cancer risk (i.e. the median of all calculated cancer risk values) of exposure for 40 years to 20 ppm styrene is low, 0.17 lympho-hematopoietic cancers in 10 3 workers, compared to the natural occurrence of this cancer of 20 per 10 3 persons. The estimated excess risk is compatible with a lack of clear positive epidemiological evidence (1, 4, 44, 50) . This kind of quantitative approaches are important to aid in identifying gaps of knowledge in this issue and demonstrate the importance of including mechanistic data into cancer risk assessment procedures. 
